Roche to present scientific progress across Alzheimer ’s disease pharmaceutical and diagnostic portfolio at 2022 AAIC Annual Meeting

Overview of two decades of research to be presented, including development ofgantenerumabDetailed results from phase II study evaluatingcrenezumab in autosomal dominant Alzheimer ' s diseaseData around biomarker selection for theElecsys Amyloid Plasma Panel, a blood-based biomarker test to aid in the detection of people with amyloid pathology, recently granted FDA Breakthrough Device DesignationBasel, 28 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that data from 41 abstracts across its portfolio of Alzheimer ’s disease pharmaceuticals and diagnostics will be presented at the 2022 Alzheimer’s Association International Conference (AAIC), which will be held in San Diego 31 July -4 August. Among the data are new presentations on Roche’s investigational subcutaneously administered anti-amyloid monoclon al antibody gantenerumab and the Elecsys® Amyloid Plasma Panel. Additionally, detailed results from the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer ' s Disease (API ADAD) Trial evaluating the investigational monoclonal antibody crenezumab will be presented to inform future Alzheimer ’s prevention research.“Following the science represents the foundation of our company. Our work in Alzheimer’s disease over the past 20 years has helped to transform disease understanding and ongoing approaches to clinical research,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Globa l Product Development. “We are p...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news